What Happened?

About the Company

Founded more than 35 years ago, Nu Skin develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry`s consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin International is a wholly owned subsidiary of NSE, which is traded on the New York Stock Exchange under the symbol.

About the Person

Mark Adams has worked in the field of bioinformatics and data analytics for more than 15 years and brings extensive experience in the strategy, design, and implementation of large-scale informatics organizations and systems in support of key strategic initiatives. He joins Good Start Genetics from Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world's largest hedge fund. Previously, Dr. Adams was a principal with Booz Allen Hamilton, where he developed a leading biomedical informatics consulting practice with a primary focus on informatics strategy for clients in the commercial, government, and non-profit markets. A pioneer in the use, development and deployment of large-scale, open-source software in the national and international bioinformatics community, Dr. Adams is also an expert on building communities comprised of academic, industry, and government partners to fund and address health care issues. Dr. Adams led some of the earliest commercial bioinformatics efforts to explore and use genomic and genetic variation data at Variagenics (Cambridge, MA,) where he was vice president of bioinformatics, and Incyte (Palo Alto, CA) where he worked with Temple Smith, Ph.D., to build the company's first informatics pipeline, supporting high-throughout SNP genomics. Dr. Adams holds a B.A. from Oberlin College and a Ph.D. from Baylor College of Medicine.